Thrombotic microangiopathy complicates 0.8%-15% of kidney transplants and significantly affects graft and patient survival; distinguishing complement-mediated disease from other triggers is critical, because complement-mediated TMA does not respond to supportive care, needs long-term anticomplement therapy and carries a high risk of recurrence.